ARTICLE | Clinical News
Boceprevir: Updated Phase II data
August 11, 2008 7:00 AM UTC
Top line data from the international Phase II SPRINT-1 trial in 595 patients with genotype 1 HCV showed SVR 24 was 56% for the 103 patients receiving PEG-Intron peginterferon alfa-2b and Rebetol rib...